Abstract:To assess the impact of vaccines on clinical outcomes among hospitalized COVID-19-infected patients requiring oxygen supplementation during the Beijing Omicron outbreak. We conducted a retrospective cohort study at Beijing Chaoyang Hospital, Capital Medical University, from November 15, 2022, to March 31, 2023. Vaccination statuses were categorized into 3 doses, 2 doses, and unvaccinated (0 dose). The primary outcome was 28-day all-cause mortality. Secondary outcomes included poor outcomes, intensive care unit admission, cardiovascular thromboembolism events, and hospital readmission. Among the included patients, 117 were 2 doses, 285 received booster doses, and 503 were unvaccinated. After propensity score inverse probability weighting, the 3 doses group showed a significantly lower 28-day all-cause mortality compared to the unvaccinated group (inverse probability of treatment weighting-adjusted HR: 0.64, 95% CI: 0.50–0.81). No significant difference was observed in all-cause mortality between the 2 doses and unvaccinated groups. No significant differences were observed in secondary outcome analyses when comparing the 3 doses or 2 doses group to the unvaccinated group. Subgroup analysis revealed significant benefits of booster vaccination in patients with shorter symptom duration, lower Charlson Comorbidity Index, and without immunosuppression status. Our study highlights the significant reduction in all-cause mortality among hospitalized Omicron-infected patients who received a third dose vaccine. These findings underscore the importance of prioritizing booster vaccinations, especially among the elderly. Further research is warranted to confirm and extend these observations.

What problem does this paper attempt to address?

The problem that this paper attempts to solve is the impact of vaccine boosters on the clinical outcomes of hospitalized COVID - 19 patients requiring oxygen supplementation during the Omicron epidemic in Beijing. Specifically, the study aims to evaluate the effect of receiving three doses of vaccines compared with being unvaccinated or only receiving two doses of vaccines in reducing the 28 - day all - cause mortality and other adverse outcomes (such as intensive care unit admission, cardiovascular thromboembolic events, and readmission). ### Research Background Since the emergence of the coronavirus disease 2019 (COVID - 19) in 2019, the number of global infections and related deaths has risen sharply, causing serious concerns worldwide. In order to prevent virus transmission and reduce symptomatic infections, vaccines have been widely distributed to prevent infection in the uninfected and disease progression. Although the global vaccination rate has increased, with the continuous emergence of SARS - CoV - 2 variants (such as Omicron), the number of breakthrough infections and reinfections has increased significantly. Therefore, the protective efficacy of vaccines has gradually shifted from preventing infection to slowing down disease progression and reducing the severity of COVID - 19. ### Research Objectives This study evaluated the impact of receiving three doses of vaccines on the clinical outcomes of hospitalized COVID - 19 patients requiring oxygen supplementation during the Omicron epidemic in Beijing through a retrospective cohort study. The primary outcome measure was the 28 - day all - cause mortality, and the secondary outcome measures included adverse outcomes (such as mechanical ventilation and death), intensive care unit admission, cardiovascular thromboembolic events, and readmission. ### Research Methods - **Research Design**: Retrospective cohort study, with data from COVID - 19 patients hospitalized in Beijing Chaoyang Hospital from November 15, 2022 to March 31, 2023. - **Inclusion Criteria**: Patients aged ≥18 years and diagnosed with COVID - 19 infection at hospitalization. - **Exclusion Criteria**: Patients who did not require supplemental oxygen therapy at admission, had no vaccination data, and had their last vaccination within 14 days. - **Data Analysis**: Inverse probability of treatment weighting (IPTW) was used to adjust for potential confounding factors, and the Cox regression model was used to estimate the hazard ratio (HR) of each outcome and its 95% confidence interval (CI). ### Main Findings - **Primary Outcome**: The 28 - day all - cause mortality in patients who received three doses of vaccines was significantly lower than that in unvaccinated patients (IPTW - adjusted HR: 0.64, 95% CI: 0.50 - 0.81). There was no significant difference between patients who received two doses of vaccines and unvaccinated patients. - **Secondary Outcome**: There was no significant difference between patients who received three doses of vaccines and unvaccinated patients in terms of adverse outcomes, intensive care unit admission, cardiovascular thromboembolic events, and readmission. ### Sub - group Analysis - **Symptom Duration**: Among patients with a symptom duration ≤5 days before admission, receiving three doses of vaccines significantly reduced the 28 - day all - cause mortality (IPTW - adjusted HR: 0.61, 95% CI: 0.50 - 0.74). - **Charlson Comorbidity Index (CCI)**: Among patients with CCI < 3, receiving three doses of vaccines significantly reduced the 28 - day all - cause mortality (IPTW - adjusted HR: 0.64, 95% CI: 0.53 - 0.78). - **Immunosuppressive State**: Among patients without an immunosuppressive state, receiving three doses of vaccines significantly reduced the 28 - day all - cause mortality (IPTW - adjusted HR: 0.84, 95% CI: 0.77 - 0.91). ### Conclusion This study provides strong evidence to support that receiving three doses of inactivated vaccines can significantly reduce the 28 - day all - cause mortality in hospitalized Omicron - infected patients. These findings emphasize the importance of prioritizing booster vaccinations, especially in the elderly population. Future studies should further verify and expand these observations.

Booster vaccines dose reduced mortality in hospitalized COVID-19 patients requiring oxygen supplementation: Evidence from the Beijing Omicron outbreak

Omicron COVID-19 Variant Outcomes and Vaccination in Non-Severe and Non-Critical Patients at Admission

Effect of inactivated vaccine boosters against severe and critical COVID‐19 during the Omicron BA.5 wave: A retrospective analysis of hospitalized patients in China

Effectiveness of booster vaccination with inactivated COVID-19 vaccines against SARS-CoV-2 Omicron BA.2 infection in Guangdong, China: a cohort study

Protection of prior SARS-CoV-2 infection, COVID-19 boosters, and hybrid immunity against Omicron severe illness: A population-based cohort study of five million residents in Canada

Inactivated COVID-19 vaccines booster dose shortened the viral shedding time of patients infected with the Omicron variant BA.2

Risk factors for COVID-19 hospitalisation after booster vaccination during the Omicron period: A French nationwide cohort study

Inactivated SARS-CoV-2 Vaccine Booster Against Omicron Infection among Quarantined Close Contacts.

The effectiveness of booster vaccination of inactivated COVID-19 vaccines against susceptibility, infectiousness, and transmission of omicron BA.2 variant: a retrospective cohort study in Shenzhen, China

A Case–case Study on the Effect of Primary and Booster Immunization with China-produced COVID-19 Vaccines on Prevention of Pneumonia and Viral Load among Vaccinated Persons Infected by Delta and Omicron Variants

New Insights into Three Trajectories of Omicron-related All-Cause Death Reduced by COVID-19 Booster Vaccination

Evaluation of COVID-19 vaccines in primary prevention against infections and reduction in severity of illness following the outbreak of SARS-CoV-2 omicron variant in Shanghai

Increased antibody titers but induced T cell AICD and apoptosis response in COVID-19 convalescents by inactivated vaccine booster

Real-world effectiveness of inactivated vaccine on COVID-19 patients with comorbidities

Vaccination Effects on Post-Infection Outcomes in the Omicron BA.2 Outbreak in Shanghai

COVID-19 Vaccination Coverage among 42,565 Adults Amid the Spread of Omicron Variant in Beijing, China

The Effectiveness of the Third Dose of COVID-19 Vaccine: When Should It Be Performed?

Effectiveness of inactivated COVID-19 vaccines in preventing COVID-19-related hospitalization during the Omicron BF.7-predominant epidemic wave in Beijing, China: a cohort study

Association of COVID-19 Vaccination and Clinical Severity of Patients Infected with Delta or Omicron Variants — China, May 21, 2021–February 28, 2022

Effectiveness of inactivated COVID-19 vaccines among older adults in Shanghai: retrospective cohort study

Relative Effectiveness and Waning of a Third Dose of mRNA COVID-19 Vaccine in Medicare Beneficiaries Aged 65 Years and Older during the BA.1/BA.2 Omicron Period